Literature DB >> 10943787

Endogenous fibrinolysis in patients with lower extremity ischemia.

V Treska1, J Valenta, L Pecen, O Topolcan.   

Abstract

To explore the relationship between disorders of endogenous fibrinolysis and thrombosis in patients with lower extremity ischemia, we measured the activity of tissue plasminogen activator (tPAac) and plasminogen activator inhibitor (PAlac) and the antigens of tissue plasminogen activator (tPAa) and inhibitor (PAla) in plasma from 420 patients treated for lower extremity ischemia. Values and ratios observed were compared with those in healthy volunteers. Additionally, values and ratios in the patients were examined with respect to the severity of ischemia and site of atherosclerotic occlusion or stenosis (pelvic compared with femoropopliteal or crural). Patients with lower extremity ischemia had higher plasma concentrations of PAla (p<0.01) and PAlac (p<0.0001) than healthy volunteers. In patients with rest pain or gangrene, the ratio of tPAac to PAlac was higher than in patients with claudication (p<0.05). The elevation of tPAac in patients with the more severe form of lower extremity ischemia is probably the feedback protective reaction on prothrombotic mechanisms of the organism suffered from severe atherosclerosis. Results did not vary according to the site of occlusion or stenosis. Our study found defects in endogenous fibrinolysis in patients with lower extremity ischemia. A defect in fibrinolysis may contribute to the development of thrombosis in native arteries and bypasses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943787     DOI: 10.1007/s100169910076

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  1 in total

1.  Ischaemia-reperfusion injury impairs tissue plasminogen activator release in man.

Authors:  Christian M Pedersen; Gareth Barnes; Michael R Schmidt; Hans Erik Bøtker; Rajesh K Kharbanda; David E Newby; Nicholas L Cruden
Journal:  Eur Heart J       Date:  2011-10-11       Impact factor: 29.983

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.